Common · Knowledge
Rilmazafone
Chemical compound
Rilmazafone (リスミー, brand name Rhythmy; developmental code 450191-S) is a water-soluble prodrug developed by Shionogi and approved in Japan for the treatment of insomnia and as a pre-anesthetic agent. It is not a benzodiazepine in the pharmacological or structural sense — the parent compound contains no diazepine ring and has no affinity for benzodiazepine receptors — but is converted inside the body into several active benzodiazepine metabolites, principally rilmazolam, which produce sedative and hypnotic effects.
From Wikipedia
Rilmazafone (リスミー, brand name Rhythmy; developmental code 450191-S) is a water-soluble prodrug developed by Shionogi and approved in Japan for the treatment of insomnia and as a pre-anesthetic agent. It is not a benzodiazepine in the pharmacological or structural sense — the parent compound contains no diazepine ring and has no affinity for benzodiazepine receptors — but is converted inside the body into several active benzodiazepine metabolites, principally rilmazolam, which produce sedative and hypnotic effects. Outside Japan, rilmazafone has appeared as a new psychoactive substance (NPS) and has been implicated in fatal overdoses in Europe and North America.
Text: Wikipédia, CC BY-SA 4.0. · Image: Vaccinationist (Public domain) ·
